Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake.
作者信息
Zibelman Matthew, Plimack Elizabeth R
机构信息
Hematology/Oncology, Fox Chase Cancer Center, Temple Health, 333 Cottman Ave, Philadelphia, PA 19111, USA.
出版信息
Immunotherapy. 2018 Mar 1;10(6):423-425. doi: 10.2217/imt-2018-0007.
PMID:29562856
Abstract
摘要
相似文献
1
Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake.
Immunotherapy. 2018 Mar 1;10(6):423-425. doi: 10.2217/imt-2018-0007.
2
Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.
Immunotherapy. 2017 May;9(6):463-466. doi: 10.2217/imt-2017-0033.
3
Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma.
Nat Rev Clin Oncol. 2018 Feb;15(2):73-74. doi: 10.1038/nrclinonc.2017.184. Epub 2017 Dec 5.
4
Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer.
Immunotherapy. 2017 Sep;9(10):781-784. doi: 10.2217/imt-2017-0073.
5
Treatment of Metastatic Urothelial Cancer in 2018.
JAMA Oncol. 2019 Jun 1;5(6):904-905. doi: 10.1001/jamaoncol.2019.0182.
6
Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers.
Urol Oncol. 2017 Dec;35(12):676-677. doi: 10.1016/j.urolonc.2017.09.023. Epub 2017 Oct 18.
7
Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
Curr Opin Urol. 2018 Jan;28(1):1-7. doi: 10.1097/MOU.0000000000000457.
8
Biomarkers for immunotherapy in urological cancers.
Curr Opin Urol. 2018 Jan;28(1):25-28. doi: 10.1097/MOU.0000000000000465.
9
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Curr Urol Rep. 2018 Nov 7;19(12):109. doi: 10.1007/s11934-018-0851-7.
10
Update of systemic immunotherapy for advanced urothelial carcinoma.
Urol Oncol. 2017 Dec;35(12):678-686. doi: 10.1016/j.urolonc.2017.09.021. Epub 2017 Oct 25.
引用本文的文献
1
Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach.
Cancers (Basel). 2021 Nov 29;13(23):6016. doi: 10.3390/cancers13236016.
Zotero 插件